ARTICLE | Discovery & Translation
Translational highlights to watch for at AACR
BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference
March 12, 2022 1:42 AM UTC
The booming targeted degradation space continues to advance through preclinical presentations at the 2022 meeting of the American Association for Cancer Research (AACR).
Among the companies presenting are Kymera Therapeutics Inc. (NASDAQ:KYMR), which will characterize its heterobifunctional MDM2 degrader KT-253 in cellular and mouse models of leukemia; and South Korea-based Orum Therapeutics Inc., whose antibody-neodegrader conjugate (AnDC) ORM-5029 degrades the translation termination factor GSPT1 in HER2-expressing tumors cells, via intracellular delivery of an IMiD-based molecular glue. ...